Fresh controversy has emerged around the union government's proposed draft regulations governing the use of animals in laboratory experiments. Animal welfare activist and People for Animals trustee Gauri Maulekhi has raised significant objections to the planned amendments, cautioning that the draft provisions threaten to unravel the institutional safeguards painstakingly established over decades. According to her evaluation, the repercussions of these regulatory shifts extend far beyond the direct suffering inflicted on voiceless animals, directly endangering the credibility, precision, and public safety standards of scientific and pharmaceutical research in the country. Since animals cannot articulate their distress, human compassion and stringent external oversight have historically formed the bedrock of laboratory ethics.
Weakening Decades of Regulatory Safeguards
With nearly 30 years of engagement in animal protection legislation, Maulekhi described the current draft as deeply alarming. In her view, the emergence of such regressive proposals points to two distinct possibilities. Either the officials responsible for drafting the policy lack a basic comprehension of established statutory frameworks, or the rules have been crafted to grant commercially convenient concessions to specific industrial interests. She emphasised that the fallout from these changes will not remain confined to experimental subjects, but will inevitably affect scientific integrity, pharmaceutical manufacturing, and the health of the general public. Instead of diluting existing protective mechanisms, the regulatory apparatus should have been strengthened to align with modern scientific standards.
Self-Approval Powers and Inherent Conflict of Interest
Highlighting what she termed the most hazardous provision in the entire draft, Maulekhi pointed out that individual laboratories are being granted the autonomy to decide whether a particular experiment requires formal government approval or can proceed internally. Furthermore, research facilities will have the authority to self-classify the severity of pain an animal is subjected to during a trial. Characterising this setup as a blatant conflict of interest, she explained that within the proposed six-member institutional ethics committees, four representatives will belong to the host institution itself, with only two external members. Such a composition enables institutional insiders to easily pass approvals in their own favour, severely crippling independent regulatory oversight and objective appraisal.
Erosion of Scientific Due Diligence and Pre-Trial Scrutiny
Detailing standard research protocols, Maulekhi explained that any animal study traditionally begins with an exhaustive experimental protocol. This submission must specify the exact number of animals required, the procedural interventions involved, the therapeutic compounds or chemicals administered, and the explicit scientific justification for the work. Prior to commencement, rigorous evaluations must determine whether non-animal alternatives could achieve the same outcomes, whether the specimen count could be curtailed, and whether the proposed project is genuinely necessary. Historically, these determinations were closely scrutinized through state-monitored checks. Under the new draft framework, however, facilities can independently greenlight experiments that they label as low pain, bypassing external evaluation entirely.
Concerns Over Open-Market Procurement and Strays
Another contentious clause in the draft permits research facilities to procure certain farm animals, birds, and aquatic species from open commercial markets whenever registered laboratory breeders are unavailable. Maulekhi raised serious alarms over this loophole, warning that it opens the door to stray dogs, monkeys, and cattle from adjacent neighborhoods being rounded up for laboratory procedures. Beyond the severe ethical breach, she highlighted the scientific risks involved: unconditioned animals sourced from streets or wilderness carry undiagnosed preexisting illnesses, parasites, and latent infections that introduce unpredictable biological variables. Formulating medicinal therapies based on contaminated, unstable baseline data poses severe risks to human clinical applications.
Documented Cruelty and Severe Laboratory Testing Practices
Describing the harrowing physical interventions routinely endured by laboratory subjects, Maulekhi noted that evaluating bone-repair pharmaceuticals often involves deliberately fracturing the bones of rabbits. In toxicological clearance assessments, animals are administered escalating chemical concentrations until 50 percent of the experimental cohort dies, a procedure known as the LD-50 test. She also cited ocular toxicity trials where chemical irritants are dripped directly into the eyes of conscious rabbits, as well as helmet-impact verifications where conscious monkeys have their heads subjected to mechanical pressure. She warned that easing regulations on such procedures removes essential safeguards against extreme cruelty.
Five-Year Repeat Experiments and Removal of Mandatory Pain Relief
Maulekhi highlighted that under the proposed terms, a single animal can be subjected to repeated experimental procedures across an extended timeframe of five years. She stated that whereas prior regulations strictly required the mandatory administration of anaesthesia and post-procedural pain relief, the new draft systematically removes these vital safeguards. Furthermore, she stressed the psychological devastation experienced by captive animals, noting that trauma is not confined to physical wounds. Confined subjects endure profound stress, loneliness, isolation from their social groups, and severe depression. Depriving an animal of food for long intervals or preventing normal species-specific behaviors constitutes immense suffering that cannot be captured solely by physical pain metrics.
Divergence From Established International Precedents
Contrasting the proposed Indian draft with global standards, Maulekhi cited the European Union's 2010 directive on the protection of animals used for scientific purposes. Under EU law, researchers must legally demonstrate why an experiment cannot be conducted using non-animal methodologies, enforce strict caps on animal counts, and maintain structured post-study rehabilitation programs. In sharp contrast, India's prospective guidelines offer sweeping procedural exemptions to testing establishments. She cautioned that this regulatory discrepancy could turn India into a convenient destination for hazardous, poorly regulated trials rejected by other nations, effectively transforming the country into an outsourced research dumping ground and animal torture chamber.
Replacement of Surprise Inspections With Advance Notices
The dilution of on-site monitoring mechanisms emerged as another major concern, with Maulekhi noting that existing surprise inspection protocols are set to be replaced by mandatory advance warnings. She pointed out that alerting laboratory administrations prior to visits provides wrongdoers ample opportunity to conceal infractions, sanitize poor housing environments, and hide unapproved testing apparatus. Recalling an earlier surprise inspection, she described discovering 27 dead snakes inside the toxicology laboratory of a major medical college, including an approximately 19-foot-long female king cobra. In that instance, the oversight committee was able to intervene decisively because the inspection took place without prior warning, an intervention that pre-scheduled visits would completely prevent.
Urgent Appeal for Public Submissions Ahead of November 5
Maulekhi concluded by stressing that India possesses significant potential to lead global pharmaceutical and biomedical research through advanced technologies. The strategic adoption of artificial intelligence, high-fidelity computer simulations, and microphysiological models makes extensive animal reliance increasingly obsolete. However, compromising oversight protocols damages international scientific standing rather than advancing progress. She urged citizens, research scientists, healthcare professionals, industrial bodies, and animal protection advocates to submit formal objections and recommendations on the draft framework before the November 5 deadline, ensuring future policies foster genuine scientific advancement rather than ethical regression.
